However, GNAS mutations were found exclusively in 11 of the 12 (91.6%) patients with MD-IPMN (p < 0.01), whereas KRAS mutations were identified in both diseases. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.